Home >  Orthopaedics >  Orthopaedics News >  Upadacitinib found...

Upadacitinib found effective for psoriatic arthritis patients, Finds Study

Written By :  Dr. Nandita Mohan
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-03-10 15:17 GMT   |   Update On 2021-03-10 15:17 GMT
Advertisement

According to recent research, it has been found out that patients with active PsA who had inadequate response or intolerance to at least one biologic DMARD, upadacitinib found effective than placebo in improving signs and symptoms of PsA.

The study is published in the Annals of the Rheumatic Diseases.

Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). Therefore, Philip J Mease and colleagues from the Department of Rheumatology, Swedish Medical Center, Seattle, Washington, USA conducted the present study to evaluate the upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying antirheumatic drug (DMARD).
In this 24-week randomised, placebo-controlled, double-blind, phase 3 trial, 642 patients were randomised (2:2:1:1) to once per day upadacitinib 15 mg or 30 mg, placebo followed by upadacitinib 15 mg or placebo followed by upadacitinib 30 mg at week 24. The primary endpoint was the proportion of patients achieving American College of Rheumatology (ACR) 20 response at week 12. Achievement of minimal disease activity (MDA) was assessed at week 24. Treatment-emergent adverse events are reported for all patients who received at least one dose of trial drug.
Advertisement
The following findings were highlighted-
a. At week 12, significantly more patients receiving upadacitinib 15 mg and 30 mg versus placebo achieved ACR20 (56.9% and 63.8% vs 24.1%; p<0.001 for both comparisons).
b. At week 24, MDA was achieved by more upadacitinib 15 mg-treated (25.1%) and 30 mg-treated patients (28.9%) versus placebo (2.8%; p<0.001 for both comparisons).
c. Generally, the rates of treatment-emergent adverse events were similar with placebo and upadacitinib 15 mg and higher with upadacitinib 30 mg at week 24.
d. Rates of serious infections were 0.5%, 0.5% and 2.8% with placebo, upadacitinib 15 mg and upadacitinib 30 mg, respectively.

Hence, the authors concluded that "In this trial of patients with active PsA who had inadequate response or intolerance to at least one biologic DMARD, upadacitinib 15 mg and 30 mg was more effective than placebo over 24 weeks in improving signs and symptoms of PsA."


Tags:    
Article Source : Annals of the Rheumatic Diseases

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Gout Patients Face Higher Risk of Chronic Opioid Use, VA Study Finds

Emphysema in smokers associated with low bone mineral density and higher fracture risk: Study

Novel Mini External Fixation Technique effective treatment option for unstable and complex phalynx fractures in hand: Study

Cycling intervention improved self-reported function in hip osteoarthritis patients: Study

Obese Children Face Nearly 5-Fold Higher Risk of Fractures, Study Finds

Conus Medullaris Level Not Linked to CSF Leak Risk in Spinal Surgery, Finds Study

Tibrolin D alleviates pain and enhances wound healing with efficacy comparable to diclofenac: study

Iontophoresis and low-dye taping are effective conservative interventions for plantar fasciitis: study